Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis.

A Laura Nijstad Natasha K A Van EijkelenburgKathelijne C J M KraalMarieke J M MeijsClara T M M de KanterMarc R Lilien Alwin D R Huitema

Published in: Cancer chemotherapy and pharmacology (2020)

This report shows that it is feasible to measure AUCs for both drugs and to individualize the dose of these drugs according to the PK results and clinical parameters. Our advice for future cases would be to calculate the starting dose of carboplatin using the (pediatric) Calvert formula, assuming a dialytic clearance of zero, and to adjust the dose if required, based on therapeutic drug monitoring.

Keyphrases

peritoneal dialysis
end stage renal disease
phase ii study
chronic kidney disease
randomized controlled trial
current status
squamous cell carcinoma
phase iii
human milk
double blind
low birth weight